Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Immunogenicity and Safety of a Meningococcal A Conjugate Vaccine in Africans

15 Jun 2011

Abstract excerpt

BACKGROUND: Group A meningococci are the source of major epidemics of meningitis in Africa. An affordable, highly immunogenic meningococcal A conjugate vaccine is needed. METHODS: We conducted two studies in Africa to evaluate a new MenA conjugate vaccine (PsA-TT). In study A, 601 children, 12 to 23 months of age, were randomly assigned to receive PsA-TT, a quadrivalent polysaccharide reference vaccine (PsACWY),...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bacterial Infections and Vaccines
Share to Pneumonia and Respiratory Infections
Share to Virology and Viral Diseases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 21675889
DOI: 10.1056/nejmoa1003812

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Immunogenicity and Safety of a Meningococcal A Conjugate Vaccine in AfricansPMID 21675889Read ↗

Meningococcal Serogroup ACWYX Conjugate Vaccine in Malian ToddlersSemantic proximity Read ↗

Safety and Immunogenicity of a Serogroups A/C Neisseria meningitidis Oligosaccharide—Protein Conjugate Vaccine in Young ChildrenSemantic proximity Read ↗

A meningococcal NOMV-FHbp vaccine for Africa elicits broader serum bactericidal antibody responses against serogroup B and non-B strains than a licensed serogroup B vaccineSemantic proximity Read ↗

The Diversity of Meningococcal Carriage Across the African Meningitis Belt and the Impact of Vaccination With a Group A Meningococcal Conjugate Vaccine.Semantic proximity Read ↗

MATS: Global coverage estimates for 4CMenB, a novel multicomponent meningococcal B vaccineSemantic proximity Read ↗

A Bivalent Meningococcal B Vaccine in Adolescents and Young AdultsSemantic proximity Read ↗

From research to licensure and beyond: clinical development of MenB-FHbp, a broadly protective meningococcal B vaccineSemantic proximity Read ↗

Immunogenicity and safety of a booster dose of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in adolescents and adults: a Phase III randomized studySemantic proximity Read ↗

Meningococcal serogroup B vaccines: Estimating breadth of coverageSemantic proximity Read ↗

Immunogenicity of Two Investigational Serogroup B Meningococcal Vaccines in the First Year of LifeSemantic proximity Read ↗

Serum Bactericidal Antibody Responses of Adults Immunized with the MenB-4C Vaccine against Genetically Diverse Serogroup B Meningococci.Semantic proximity Read ↗

Correlates of protection for meningococcal surface protein vaccines: lessons from the pastSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.